Aurobindo Pharma Limited has notified the stock exchanges of a key leadership change at one of its wholly owned subsidiaries. Dr. Sanjay Chaturvedi has tendered his resignation as Chief Executive Officer of Apitoria Pharma Private Limited, citing his decision to move on to a different opportunity. The intimation was filed in compliance with Regulation 30 of the applicable listing regulations.

Leadership Change at Apitoria Pharma

The resignation was communicated to both the National Stock Exchange of India Limited and BSE Limited on May 4, 2026. Dr. Chaturvedi has been relieved from his services with effect from the close of business hours on May 4, 2026. The disclosure was signed by B. Adi Reddy, Company Secretary of Aurobindo Pharma Limited.

Key details of the development are summarised below:

About the Entities Involved

Apitoria Pharma Private Limited is a wholly owned subsidiary of Aurobindo Pharma Limited. Aurobindo Pharma Limited is headquartered at Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, Telangana, India. The company's registered office is located at Plot No. 2, Maithrivihar, Ameerpet, Hyderabad, Telangana, India.

The filing was made to the Listing Department of the National Stock Exchange of India Limited and the Corporate Relations Department of BSE Limited as part of the company's regulatory disclosure obligations.

Aurobindo Pharma 's wholly owned subsidiary CuraTeQ Biologics Private Limited has achieved a significant regulatory milestone with Health Canada's approval of its bevacizumab biosimilar. The company formally announced on May 1, 2026, through a regulatory filing that it received Notice of Compliance (NOC) from Health Canada's Biologics and Radiopharmaceutical Drugs Directorate (BRDD) for Bevqolva™, marking another key market entry for the biosimilar product used in cancer treatment.

Regulatory Approval Details

Health Canada's NOC represents formal marketing authorization granted after a successful regulatory review process. The approval confirms that Bevqolva™ meets stringent regulatory standards for safety, efficacy, and quality, demonstrating comparability to the reference biologic drug under the Food and Drug Regulations.

Product Profile and Mechanism

Bevacizumab is a humanized monoclonal antibody that functions as an angiogenesis inhibitor. The drug works by blocking vascular endothelial growth factor A (VEGF-A), which plays a crucial role in the formation of new blood vessels. This mechanism of action effectively slows tumor vascular growth and provides therapeutic benefits in treating multiple cancer types, including colorectal and lung cancers.

The originator product, Avastin, is marketed by Roche/Genentech and represents a significant market opportunity for biosimilar competitors. Bevqolva™ offers healthcare systems and patients an alternative treatment option with comparable efficacy and safety profiles.

Global Market Expansion

CuraTeQ Biologics has been systematically expanding Bevqolva™'s global presence across multiple regulatory jurisdictions. The company achieved notable success in 2025 when it secured marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) and successfully launched the product commercially for patients across the United Kingdom.

Pipeline and Future Prospects

Beyond Bevqolva™, CuraTeQ Biologics maintains an active biosimilar development pipeline with Health Canada. The company currently has two additional biosimilar applications under review by the Canadian regulatory authority, indicating continued expansion of its product portfolio in the Canadian market.

The European Medicines Agency review through the Committee for Medicinal Products for Human Use (CHMP) represents another significant opportunity for market expansion, potentially providing access to the broader European Union market for Bevqolva™.